Abigail E. Case

422 total citations
8 papers, 232 citations indexed

About

Abigail E. Case is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Abigail E. Case has authored 8 papers receiving a total of 232 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Hematology, 3 papers in Genetics and 2 papers in Molecular Biology. Recurrent topics in Abigail E. Case's work include Acute Myeloid Leukemia Research (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Chronic Myeloid Leukemia Treatments (3 papers). Abigail E. Case is often cited by papers focused on Acute Myeloid Leukemia Research (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Chronic Myeloid Leukemia Treatments (3 papers). Abigail E. Case collaborates with scholars based in United States, Austria and France. Abigail E. Case's co-authors include Elizabeth M. Garry, Jeremy A. Rassen, Gerald B. Downes, Martin Sattler, Ellen Weisberg, Chengcheng Meng, Richard M. Stone, Jinhua Wang, Nathanael S. Gray and Prafulla C. Gokhale and has published in prestigious journals such as PLoS ONE, British Journal of Cancer and Clinical Pharmacology & Therapeutics.

In The Last Decade

Abigail E. Case

8 papers receiving 227 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Abigail E. Case United States	6	62	50	46	33	26	8	232
James Valentine United States	4	129 2.1×	6 0.1×	74 1.6×	13 0.4×	18 0.7×	7	315
Kalotina Machini United States	9	109 1.8×	9 0.2×	32 0.7×	3 0.1×	5 0.2×	15	518
Eden Haverfield United States	13	241 3.9×	40 0.8×	4 0.1×	2 0.1×	23 0.9×	23	536
Saiju Pyarajan United States	9	102 1.6×	14 0.3×	9 0.2×	6 0.2×	59 2.3×	23	243
Haris Babačić Sweden	7	69 1.1×	22 0.4×	8 0.2×		31 1.2×	16	266
Seth Robey United States	6	186 3.0×	4 0.1×	9 0.2×	6 0.2×	53 2.0×	10	323
Łukasz Kozera Poland	11	215 3.5×	12 0.2×	21 0.5×	1 0.0×	15 0.6×	21	425
T E Romer Poland	12	202 3.3×	3 0.1×	20 0.4×	9 0.3×	54 2.1×	22	366
Phillip Gray United States	8	123 2.0×	4 0.1×	11 0.2×	3 0.1×	17 0.7×	11	357
Ian Winburn United Kingdom	10	203 3.3×	69 1.4×	6 0.1×	1 0.0×	15 0.6×	20	349

Countries citing papers authored by Abigail E. Case

Since Specialization

Citations

This map shows the geographic impact of Abigail E. Case's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Abigail E. Case with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Abigail E. Case more than expected).

Fields of papers citing papers by Abigail E. Case

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Abigail E. Case. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Abigail E. Case. The network helps show where Abigail E. Case may publish in the future.

Co-authorship network of co-authors of Abigail E. Case

This figure shows the co-authorship network connecting the top 25 collaborators of Abigail E. Case. A scholar is included among the top collaborators of Abigail E. Case based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Abigail E. Case. Abigail E. Case is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Garry, Elizabeth M., et al.. (2021). The Role of Real‐World Evidence in FDA‐Approved New Drug and Biologics License Applications. Clinical Pharmacology & Therapeutics. 111(1). 135–144. 92 indexed citations

Weisberg, Ellen, Chengcheng Meng, Abigail E. Case, et al.. (2020). Effects of the multi‐kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. Journal of Cellular and Molecular Medicine. 24(5). 2968–2980. 19 indexed citations

Weisberg, Ellen, Chengcheng Meng, Abigail E. Case, et al.. (2020). Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia. 34(9). 2543–2543. 1 indexed citations

Yang, Jing, Chengcheng Meng, Ellen Weisberg, et al.. (2020). Inhibition of the deubiquitinase USP10 induces degradation of SYK. British Journal of Cancer. 122(8). 1175–1184. 22 indexed citations

Weisberg, Ellen, Chengcheng Meng, Abigail E. Case, et al.. (2020). The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations. Journal of Cellular and Molecular Medicine. 24(3). 2145–2156. 2 indexed citations

Case, Abigail E., Dalia Larios, Chengcheng Meng, et al.. (2020). Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM). Cancers. 13(1). 7–7. 17 indexed citations

Weisberg, Ellen, Chengcheng Meng, Abigail E. Case, et al.. (2019). Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU‐285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. British Journal of Haematology. 187(4). 488–501. 37 indexed citations

Case, Abigail E., et al.. (2018). Expression of the eight GABAA receptor α subunits in the developing zebrafish central nervous system. PLoS ONE. 13(4). e0196083–e0196083. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact